PPT-Canadian Cardiovascular Society Antiplatelet Guidelines

ASA NSAID DrugDrug Interaction Working Group Alan D Bell MD CCFP Wee Shian Chan MD FRCP Objectives Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet therapy in patients . Antiplatelet Guidelines. PERIOPERATIVE MANAGEMENT OF ANTIPLATELET THERAPY. Working Group: . James D. Douketis MD, FRCP(C); A. Graham . Turpie. MD, FRCP(C). Objectives. Interpret the Canadian Cardiovascular Society . Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Antiplatelet Guidelines. USE OF ANTIPLATELET THERAPY IN WOMEN WHO ARE PREGNANT OR BREASTFEEDING. Working Group: . Wee . Shian. Chan MD, FRCP(C); James D. Douketis MD, FRCP(C). Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Antiplatelet Guidelines. MANAGEMENT OF ANTIPLATELET THERAPY IN ASSOCIATION WITH MINOR BLEEDING. Working Group: . James D. Douketis MD, FRCP(C); A. Graham . Turpie. MD, FRCP(C). Objectives. Interpret the Canadian Cardiovascular Society . Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . P . Stather. , N . Dattani. , D . Sidloff. On Behalf of VERN. Background. Abdominal Aortic Aneurysm (AAA) increases cardiovascular (CV) risk. NAAASP recommends BP and lipid control. ESVS recommends antiplatelet. Thomas Savides, M.D.. Professor of Clinical Medicine. University of California, San Diego. Disclosures. None. Learning Objectives. Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Antiplatelet Guidelines. . ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working. Group: . Neesh. . Pannu. , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet . Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome Working Group: Jean-François Tanguay , MD, CSPQ, FRCP(C), FACC, FAHA, FESC; Michael P. Love, MB, ChB, MD, MRCP; and Robert C. Welsh, MD, FRCP, FACC Management of Anticoagulants & Antiplatelet Agents Pre and Post Endoscopy Thomas Savides, M.D. Professor of Clinical Medicine University of California, San Diego Disclosures None Learning Objectives Slide 1: . Target. population/question. 2. 09/01/2018. Patients with inflammatory joint disorders, particularly rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. To update the EULAR 2009 cardiovascular disease (. 12. inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD.